

Global Long-Acting Injectable (LAI) Antipsychotic Supply, Demand and Key Producers, 2023-2029

https://marketpublishers.com/r/GFCF0BA898AAEN.html

Date: May 2023

Pages: 95

Price: US\$ 4,480.00 (Single User License)

ID: GFCF0BA898AAEN

Abstracts

The global Long-Acting Injectable (LAI) Antipsychotic market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.

This report studies the global Long-Acting Injectable (LAI) Antipsychotic demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Long-Acting Injectable (LAI) Antipsychotic, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-Acting Injectable (LAI) Antipsychotic that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Long-Acting Injectable (LAI) Antipsychotic total market, 2018-2029, (USD Million)

Global Long-Acting Injectable (LAI) Antipsychotic total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Long-Acting Injectable (LAI) Antipsychotic total market, key domestic



companies and share, (USD Million)

Global Long-Acting Injectable (LAI) Antipsychotic revenue by player and market share 2018-2023, (USD Million)

Global Long-Acting Injectable (LAI) Antipsychotic total market by Type, CAGR, 2018-2029, (USD Million)

Global Long-Acting Injectable (LAI) Antipsychotic total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Long-Acting Injectable (LAI) Antipsychotic market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada and Prolixin, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Long-Acting Injectable (LAI) Antipsychotic market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.


Global Long-Acting Injectable (LAI) Antipsychotic Market, By Region:

United States

China

Europe







Abilify Maintena		
Haldol		
Otsuka Pharmaceutical		
Aristada		
Prolixin		
Key Questions Answered		
1. How big is the global Long-Acting Injectable (LAI) Antipsychotic market?		
2. What is the demand of the global Long-Acting Injectable (LAI) Antipsychotic market		
3. What is the year over year growth of the global Long-Acting Injectable (LAI) Antipsychotic market?		
4. What is the total value of the global Long-Acting Injectable (LAI) Antipsychotic market?		
5. Who are the major players in the global Long-Acting Injectable (LAI) Antipsychotic market?		
6. What are the growth factors driving the market demand?		



Contents

1 SUPPLY SUMMARY

- 1.1 Long-Acting Injectable (LAI) Antipsychotic Introduction
- 1.2 World Long-Acting Injectable (LAI) Antipsychotic Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Long-Acting Injectable (LAI) Antipsychotic Total Market by Region (by Headquarter Location)
- 1.3.1 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2029), (by Headquarter Location)
- 1.3.2 United States Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
 - 1.3.3 China Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
 - 1.3.4 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
 - 1.3.5 Japan Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
- 1.3.6 South Korea Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
- 1.3.7 ASEAN Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
- 1.3.8 India Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Long-Acting Injectable (LAI) Antipsychotic Market Drivers
- 1.4.2 Factors Affecting Demand
- 1.4.3 Long-Acting Injectable (LAI) Antipsychotic Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.2 World Long-Acting Injectable (LAI) Antipsychotic Consumption Value by Region
- 2.2.1 World Long-Acting Injectable (LAI) Antipsychotic Consumption Value by Region (2018-2023)
- 2.2.2 World Long-Acting Injectable (LAI) Antipsychotic Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.4 China Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.5 Europe Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)



- 2.6 Japan Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.7 South Korea Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.8 ASEAN Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)
- 2.9 India Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029)

3 WORLD LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTIC COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Long-Acting Injectable (LAI) Antipsychotic Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
- 3.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for Long-Acting Injectable (LAI) Antipsychotic in 2022
- 3.2.3 Global Concentration Ratios (CR8) for Long-Acting Injectable (LAI) Antipsychotic in 2022
- 3.3 Long-Acting Injectable (LAI) Antipsychotic Company Evaluation Quadrant
- 3.4 Long-Acting Injectable (LAI) Antipsychotic Market: Overall Company Footprint Analysis
 - 3.4.1 Long-Acting Injectable (LAI) Antipsychotic Market: Region Footprint
- 3.4.2 Long-Acting Injectable (LAI) Antipsychotic Market: Company Product Type Footprint
- 3.4.3 Long-Acting Injectable (LAI) Antipsychotic Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Long-Acting Injectable (LAI) Antipsychotic Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
- 4.1.2 United States VS China: Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share Comparison (2018 & 2022 & 2029)



- 4.2 United States Based Companies VS China Based Companies: Long-Acting Injectable (LAI) Antipsychotic Consumption Value Comparison
- 4.2.1 United States VS China: Long-Acting Injectable (LAI) Antipsychotic Consumption Value Comparison (2018 & 2022 & 2029)
- 4.2.2 United States VS China: Long-Acting Injectable (LAI) Antipsychotic Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Long-Acting Injectable (LAI) Antipsychotic Companies and Market Share, 2018-2023
- 4.3.1 United States Based Long-Acting Injectable (LAI) Antipsychotic Companies, Headquarters (States, Country)
- 4.3.2 United States Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023)
- 4.4 China Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue and Market Share, 2018-2023
- 4.4.1 China Based Long-Acting Injectable (LAI) Antipsychotic Companies, Company Headquarters (Province, Country)
- 4.4.2 China Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023)
- 4.5 Rest of World Based Long-Acting Injectable (LAI) Antipsychotic Companies and Market Share, 2018-2023
- 4.5.1 Rest of World Based Long-Acting Injectable (LAI) Antipsychotic Companies, Headquarters (States, Country)
- 4.5.2 Rest of World Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

- 5.1 World Long-Acting Injectable (LAI) Antipsychotic Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
 - 5.2.1 Aripiprazole
 - 5.2.2 Fluphenazine
 - 5.2.3 Haloperidol
 - 5.2.4 Others
- 5.3 Market Segment by Type
- 5.3.1 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023)
- 5.3.2 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2024-2029)



5.3.3 World Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

- 6.1 World Long-Acting Injectable (LAI) Antipsychotic Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
 - 6.2.1 Hospital
 - 6.2.2 Retail Pharmacy
 - 6.2.3 Others
- 6.3 Market Segment by Application
- 6.3.1 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023)
- 6.3.2 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2024-2029)
- 6.3.3 World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2029)

7 COMPANY PROFILES

- 7.1 Alkermes
 - 7.1.1 Alkermes Details
 - 7.1.2 Alkermes Major Business
 - 7.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.1.4 Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
- 7.1.5 Alkermes Recent Developments/Updates
- 7.1.6 Alkermes Competitive Strengths & Weaknesses
- 7.2 Eli Lilly and Company
 - 7.2.1 Eli Lilly and Company Details
 - 7.2.2 Eli Lilly and Company Major Business
- 7.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.2.4 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Eli Lilly and Company Recent Developments/Updates
 - 7.2.6 Eli Lilly and Company Competitive Strengths & Weaknesses
- 7.3 Janssen Global Services, LLC



- 7.3.1 Janssen Global Services, LLC Details
- 7.3.2 Janssen Global Services, LLC Major Business
- 7.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.3.4 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
- 7.3.5 Janssen Global Services, LLC Recent Developments/Updates
- 7.3.6 Janssen Global Services, LLC Competitive Strengths & Weaknesses
- 7.4 Abilify Maintena
 - 7.4.1 Abilify Maintena Details
 - 7.4.2 Abilify Maintena Major Business
 - 7.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.4.4 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
 - 7.4.5 Abilify Maintena Recent Developments/Updates
- 7.4.6 Abilify Maintena Competitive Strengths & Weaknesses
- 7.5 Haldol
 - 7.5.1 Haldol Details
 - 7.5.2 Haldol Major Business
 - 7.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.5.4 Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
 - 7.5.5 Haldol Recent Developments/Updates
 - 7.5.6 Haldol Competitive Strengths & Weaknesses
- 7.6 Otsuka Pharmaceutical
 - 7.6.1 Otsuka Pharmaceutical Details
 - 7.6.2 Otsuka Pharmaceutical Major Business
- 7.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.6.4 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 Otsuka Pharmaceutical Recent Developments/Updates
 - 7.6.6 Otsuka Pharmaceutical Competitive Strengths & Weaknesses
- 7.7 Aristada
 - 7.7.1 Aristada Details
 - 7.7.2 Aristada Major Business
 - 7.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.7.4 Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)



- 7.7.5 Aristada Recent Developments/Updates
- 7.7.6 Aristada Competitive Strengths & Weaknesses
- 7.8 Prolixin
 - 7.8.1 Prolixin Details
 - 7.8.2 Prolixin Major Business
 - 7.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Product and Services
- 7.8.4 Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 Prolixin Recent Developments/Updates
 - 7.8.6 Prolixin Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Long-Acting Injectable (LAI) Antipsychotic Industry Chain
- 8.2 Long-Acting Injectable (LAI) Antipsychotic Upstream Analysis
- 8.3 Long-Acting Injectable (LAI) Antipsychotic Midstream Analysis
- 8.4 Long-Acting Injectable (LAI) Antipsychotic Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. World Long-Acting Injectable (LAI) Antipsychotic Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Long-Acting Injectable (LAI) Antipsychotic Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Long-Acting Injectable (LAI) Antipsychotic Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Long-Acting Injectable (LAI) Antipsychotic Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Long-Acting Injectable (LAI) Antipsychotic Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Long-Acting Injectable (LAI) Antipsychotic Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Long-Acting Injectable (LAI) Antipsychotic Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Long-Acting Injectable (LAI) Antipsychotic Players in 2022

Table 12. World Long-Acting Injectable (LAI) Antipsychotic Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Long-Acting Injectable (LAI) Antipsychotic Company Evaluation Quadrant

Table 14. Head Office of Key Long-Acting Injectable (LAI) Antipsychotic Player

Table 15. Long-Acting Injectable (LAI) Antipsychotic Market: Company Product Type Footprint

Table 16. Long-Acting Injectable (LAI) Antipsychotic Market: Company Product Application Footprint

Table 17. Long-Acting Injectable (LAI) Antipsychotic Mergers & Acquisitions Activity

Table 18. United States VS China Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Long-Acting Injectable (LAI) Antipsychotic Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)



- Table 20. United States Based Long-Acting Injectable (LAI) Antipsychotic Companies, Headquarters (States, Country)
- Table 21. United States Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023) & (USD Million)
- Table 22. United States Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share (2018-2023)
- Table 23. China Based Long-Acting Injectable (LAI) Antipsychotic Companies, Headquarters (Province, Country)
- Table 24. China Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023) & (USD Million)
- Table 25. China Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share (2018-2023)
- Table 26. Rest of World Based Long-Acting Injectable (LAI) Antipsychotic Companies, Headquarters (States, Country)
- Table 27. Rest of World Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue, (2018-2023) & (USD Million)
- Table 28. Rest of World Based Companies Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share (2018-2023)
- Table 29. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type, (USD Million), 2018 & 2022 & 2029
- Table 30. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023) & (USD Million)
- Table 31. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2024-2029) & (USD Million)
- Table 32. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application, (USD Million), 2018 & 2022 & 2029
- Table 33. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023) & (USD Million)
- Table 34. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2024-2029) & (USD Million)
- Table 35. Alkermes Basic Information, Area Served and Competitors
- Table 36. Alkermes Major Business
- Table 37. Alkermes Long-Acting Injectable (LAI) Antipsychotic Product and Services
- Table 38. Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 39. Alkermes Recent Developments/Updates
- Table 40. Alkermes Competitive Strengths & Weaknesses
- Table 41. Eli Lilly and Company Basic Information, Area Served and Competitors
- Table 42. Eli Lilly and Company Major Business



Table 43. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product and Services

Table 44. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue,

Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Eli Lilly and Company Recent Developments/Updates

Table 46. Eli Lilly and Company Competitive Strengths & Weaknesses

Table 47. Janssen Global Services, LLC Basic Information, Area Served and Competitors

Table 48. Janssen Global Services, LLC Major Business

Table 49. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product and Services

Table 50. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic

Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Janssen Global Services, LLC Recent Developments/Updates

Table 52. Janssen Global Services, LLC Competitive Strengths & Weaknesses

Table 53. Abilify Maintena Basic Information, Area Served and Competitors

Table 54. Abilify Maintena Major Business

Table 55. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product and Services

Table 56. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Abilify Maintena Recent Developments/Updates

Table 58. Abilify Maintena Competitive Strengths & Weaknesses

Table 59. Haldol Basic Information, Area Served and Competitors

Table 60. Haldol Major Business

Table 61. Haldol Long-Acting Injectable (LAI) Antipsychotic Product and Services

Table 62. Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Haldol Recent Developments/Updates

Table 64. Haldol Competitive Strengths & Weaknesses

Table 65. Otsuka Pharmaceutical Basic Information, Area Served and Competitors

Table 66. Otsuka Pharmaceutical Major Business

Table 67. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product and Services

Table 68. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue,

Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Otsuka Pharmaceutical Recent Developments/Updates

Table 70. Otsuka Pharmaceutical Competitive Strengths & Weaknesses

Table 71. Aristada Basic Information, Area Served and Competitors



- Table 72. Aristada Major Business
- Table 73. Aristada Long-Acting Injectable (LAI) Antipsychotic Product and Services
- Table 74. Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Aristada Recent Developments/Updates
- Table 76. Prolixin Basic Information, Area Served and Competitors
- Table 77. Prolixin Major Business
- Table 78. Prolixin Long-Acting Injectable (LAI) Antipsychotic Product and Services
- Table 79. Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 80. Global Key Players of Long-Acting Injectable (LAI) Antipsychotic Upstream (Raw Materials)
- Table 81. Long-Acting Injectable (LAI) Antipsychotic Typical Customers



List Of Figures

LIST OF FIGURES

Figure 1. Long-Acting Injectable (LAI) Antipsychotic Picture

Figure 2. World Long-Acting Injectable (LAI) Antipsychotic Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Long-Acting Injectable (LAI) Antipsychotic Total Market Size (2018-2029) & (USD Million)

Figure 4. World Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Figure 5. World Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Long-Acting Injectable (LAI) Antipsychotic Revenue (2018-2029) & (USD Million)

Figure 13. Long-Acting Injectable (LAI) Antipsychotic Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 16. World Long-Acting Injectable (LAI) Antipsychotic Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 18. China Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)



Figure 20. Japan Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 23. India Long-Acting Injectable (LAI) Antipsychotic Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Long-Acting Injectable (LAI) Antipsychotic by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Long-Acting Injectable (LAI) Antipsychotic Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Long-Acting Injectable (LAI) Antipsychotic Markets in 2022

Figure 27. United States VS China: Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Long-Acting Injectable (LAI) Antipsychotic Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Type in 2022

Figure 31. Aripiprazole

Figure 32. Fluphenazine

Figure 33. Haloperidol

Figure 34. Others

Figure 35. World Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Type (2018-2029)

Figure 36. World Long-Acting Injectable (LAI) Antipsychotic Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 37. World Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Application in 2022

Figure 38. Hospital

Figure 39. Retail Pharmacy

Figure 40. Others

Figure 41. Long-Acting Injectable (LAI) Antipsychotic Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source



I would like to order

Product name: Global Long-Acting Injectable (LAI) Antipsychotic Supply, Demand and Key Producers,

2023-2029

Product link: https://marketpublishers.com/r/GFCF0BA898AAEN.html

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GFCF0BA898AAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



